Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00182143 · ClinicalTrials.gov registry record · Phase 3
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
A Phase 3 study, sponsored by McMaster University.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,659
- Enrollment target
NCT00182143: Completed Phase 3 study, sponsored by McMaster University.
NCT00182143 is a Phase 3 study that has completed, run by McMaster University. The registered enrollment target is 3,659 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (374% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00182143, a Phase 3 study, has completed, sponsored by McMaster University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,659 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
Interventions
- DRUG Unfractionated Heparin
- DRUG LMWH (Fragmin, dalteparin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,659 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00182143 record still lists
NCT00182143 is an interventional study that assigns participants to a tested intervention. Its 3,659 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (374% higher).
The record links to 0 conditions, and to 2 interventions - of which Unfractionated Heparin is the first listed.
NCT00182143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00182143 about?
NCT00182143 is a clinical study titled "PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)". The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism...
What is the current status of trial NCT00182143?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,659 participants. The study started on 2006-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00182143?
The interventions under investigation include: Unfractionated Heparin (DRUG), LMWH (Fragmin, dalteparin) (DRUG).
Who is sponsoring clinical trial NCT00182143?
This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00182143's enrollment target sits among peer trials
3,659 67th of 2000 higher than 1,934 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT07249398 · 3,650 participants · NA
Influence of Social Media Ads on Food Choice - Master Protocol
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia